Literature DB >> 22539471

Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood.

Om Prakash Singh1, Kamlesh Gidwani, Rajiv Kumar, Susanne Nylén, Stephen L Jones, Marleen Boelaert, David Sacks, Shyam Sundar.   

Abstract

Depressed cell-mediated immunity in human visceral leishmaniasis (VL) (also known as kala-azar), revealed as the inability of peripheral blood mononuclear cells (PBMCs) to respond to Leishmania antigen, remains a hallmark of and is thought to underlie the progressive nature of this disease. We recently reported the ability of a whole-blood, gamma interferon (IFN-γ) release assay to detect subclinical infections among healthy individuals living in an area where kala-azar is endemic (Bihar, India) and the surprising result that patients with active VL also secreted significant levels of antigen-specific IFN-γ in this assay. We were interested in ascertaining whether these findings would be true for a larger cohort of subjects and in employing the whole-blood assay to detect additional cytokines that might better correlate with the disease status of infected individuals. We evaluated IFN-γ, tumor necrosis factor alpha (TNF-α), and interleukin-10 (IL-10) release in 35 patients with active VL, 54 patients with VL who were cured, 27 patients with other diseases, 52 healthy controls who lived in regions where VL or kala-azar is not endemic (NEHCs [for nonendemic healthy controls]), and 147 healthy controls who lived in regions where kala-azar is endemic (EHCs [for endemic healthy controls]). The cellular responses of the EHCs were correlated with their serological antibody titers against Leishmania donovani and Phlebotomus argentipes saliva. The whole-blood cells from the majority of both active (80%) and cured (85%) VL patients, as well as 24% of EHCs with presumed subclinical infections, produced significantly elevated levels of IFN-γ. The findings do not support a severe Th1 response defect in kala-azar. Importantly, only the patients with active VL also produced IL-10, which in conjunction with IFN-γ better reflects the immune responses that distinguish individuals with active disease from cured or subclinically infected, immune individuals.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22539471      PMCID: PMC3370446          DOI: 10.1128/CVI.00143-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  27 in total

1.  Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome.

Authors:  V Peruhype-Magalhães; O A Martins-Filho; A Prata; L de A Silva; A Rabello; A Teixeira-Carvalho; R M Figueiredo; S F Guimarães-Carvalho; T C A Ferrari; R Correa-Oliveira
Journal:  Scand J Immunol       Date:  2005-11       Impact factor: 3.487

2.  Modulation of the cell-mediated immune response in kala-azar and post-kala-azar dermal leishmaniasis in relation to chemotherapy.

Authors:  A B Neogy; A Nandy; B Ghosh Dastidar; A B Chowdhury
Journal:  Ann Trop Med Parasitol       Date:  1988-02

3.  Diminished in vitro production of interleukin-1 and tumor necrosis factor-alpha during acute visceral leishmaniasis and recovery after therapy.

Authors:  J L Ho; R Badaró; A Schwartz; C A Dinarello; J A Gelfand; J Sobel; A Barral; M B Netto; E M Carvalho; S G Reed
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

4.  Application of an improved method for the recombinant k 39 enzyme-linked immunosorbent assay to detect visceral leishmaniasis disease and infection in Bangladesh.

Authors:  K M Kurkjian; L E Vaz; R Haque; C Cetre-Sossah; S Akhter; S Roy; F Steurer; J Amann; M Ali; R Chowdhury; Y Wagatsuma; J Williamson; S Crawford; R F Breiman; J H Maguire; C Bern; W E Secor
Journal:  Clin Diagn Lab Immunol       Date:  2005-12

5.  Splenic cytokine responses in Indian kala-azar before and after treatment.

Authors:  R T Kenney; D L Sacks; A A Gam; H W Murray; S Sundar
Journal:  J Infect Dis       Date:  1998-03       Impact factor: 5.226

6.  An analysis of T cell responsiveness in Indian kala-azar.

Authors:  D L Sacks; S L Lal; S N Shrivastava; J Blackwell; F A Neva
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

7.  Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis.

Authors:  O Bacellar; C Brodskyn; J Guerreiro; M Barral-Netto; C H Costa; R L Coffman; W D Johnson; E M Carvalho
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

8.  Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis.

Authors:  J P Haldar; S Ghose; K C Saha; A C Ghose
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

9.  Risk factors for kala-azar in Bangladesh.

Authors:  Caryn Bern; Allen W Hightower; Rajib Chowdhury; Mustakim Ali; Josef Amann; Yukiko Wagatsuma; Rashidul Haque; Katie Kurkjian; Louise E Vaz; Moarrita Begum; Tangin Akter; Catherine B Cetre-Sossah; Indu B Ahluwalia; Ellen Dotson; W Evan Secor; Robert F Breiman; James H Maguire
Journal:  Emerg Infect Dis       Date:  2005-05       Impact factor: 6.883

10.  Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis.

Authors:  Arlene Caldas; Cecília Favali; Dorlene Aquino; Vera Vinhas; Johan van Weyenbergh; Cláudia Brodskyn; Jackson Costa; Manoel Barral-Netto; Aldina Barral
Journal:  BMC Infect Dis       Date:  2005-12-19       Impact factor: 3.090

View more
  54 in total

1.  Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.

Authors:  M S Duthie; J Guderian; A Vallur; A Bhatia; P Lima dos Santos; E Vieira de Melo; A Ribeiro de Jesus; M Todt; D Mondal; R Almeida; S G Reed
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-10-31       Impact factor: 3.267

2.  Synergistic antigen combinations for the development of interferon gamma release assays for paucibacillary leprosy.

Authors:  R M Oliveira; E M Hungria; A de Araújo Freitas; A L O M de Sousa; M B Costa; S G Reed; M S Duthie; M M A Stefani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-03-12       Impact factor: 3.267

3.  Comparison Between Immuno-Clinicopathological Features of Experimental and Human Visceral Leishmaniasis by Leishmania donovani.

Authors:  Sheetal Saini; Anuradha Dube; Amogh Anant Sahasrabuddhe; Chandreshwar Prasad Thakur; Sumit Joshi; Keerti Rawat; Ambak Kumar Rai
Journal:  Acta Parasitol       Date:  2019-10-01       Impact factor: 1.440

4.  CD45RO+ T Cells and T Cell Activation in the Long-Lasting Immunity after Leishmania infantum Infection.

Authors:  João F Rodrigues-Neto; Gloria R Monteiro; Tatjana S L Keesen; Henio G Lacerda; Edgar M Carvalho; Selma M B Jeronimo
Journal:  Am J Trop Med Hyg       Date:  2017-12-21       Impact factor: 2.345

5.  Anti-Interleukin-10 Unleashes Transcriptional Response to Leishmanial Antigens in Visceral Leishmaniasis Patients.

Authors:  Om Prakash Singh; Genevieve Syn; Susanne Nylén; Christian Engwerda; David Sacks; Mary E Wilson; Rajiv Kumar; Jaya Chakravarty; Shyam Sundar; Jenefer M Blackwell; Michaela Fakiola
Journal:  J Infect Dis       Date:  2021-02-13       Impact factor: 5.226

6.  Asymptomatic Leishmania infection: a new challenge for Leishmania control.

Authors:  Om Prakash Singh; Epco Hasker; David Sacks; Marleen Boelaert; Shyam Sundar
Journal:  Clin Infect Dis       Date:  2014-02-27       Impact factor: 9.079

Review 7.  Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence.

Authors:  Shyam Sundar; Om Prakash Singh; Jaya Chakravarty
Journal:  Expert Rev Anti Infect Ther       Date:  2018-10-10       Impact factor: 5.091

Review 8.  Whole blood assay and visceral leishmaniasis: Challenges and promises.

Authors:  Om Prakash Singh; Shyam Sundar
Journal:  Immunobiology       Date:  2014-01-31       Impact factor: 3.144

9.  Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.

Authors:  Michael G Berg; Robert J Adams; Ratish Gambhira; Mark C Siracusa; Alan L Scott; Richard B S Roden; Gary Ketner
Journal:  Clin Vaccine Immunol       Date:  2014-07-02

10.  Tumor necrosis factor alpha neutralization has no direct effect on parasite burden, but causes impaired IFN-γ production by spleen cells from human visceral leishmaniasis patients.

Authors:  Neetu Singh; Rajiv Kumar; Christian Engwerda; David Sacks; Susanne Nylen; Shyam Sundar
Journal:  Cytokine       Date:  2016-06-30       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.